Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSC therapy in diabetic kidney disease
NCT03840343Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Oct 2019
- Primary completion
- Aug 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous adipose-derived mesenchymal stromal cells in diabetic kidney disease (DKD) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Adverse Events at 15 months. Started Oct 2019; status: terminated.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT03840343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840343.